CHALLENGES IN DRUG USE NEAR TERM AND DURING DELIVERY

Main Article Content

Dan Farine

Keywords

DRUG, DELIVERY

Abstract

There   are   currently   many   sources   for information   ranging   from   standard   textbooks going through the ten of thousands of peer reviewed article and ending with the huge amount of data accessible through the Internet.  

Abstract 82 | PDF Downloads 44

References

1. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. [Clinical Trial. Journal Article] Journal of Psychiatry & Neuroscience. 2001; 26(1):44-8.
2. Annas GJ, Elias S. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. American Journal of Public Health. 1999; 89(1):98 -101.
3. Pole M, Einarson A, Pairaudeau N, Einarson T, Koren G. Drug labeling and risk perception s of teratogenicity: a survey of pregnant Canadian women and their health professionals. [Journal Article] Journal of Clinical Pharmacology. 2000; 40(6):573-7.
4. Pole M, Einarson A, Pairaudeau N, Einarson T, Koren G. Drug labeling and risk perception s of teratogenicity: a survey of pregnant Canadian women and their health professionals. [Journal Article] Journal of Clinical Pharmacology. 2000; 40(6):573-7.
5. Gaskin IM. The problem with Cytotec is that it has not been approved for obstetrical use. [Editorial] Birth Gazette. 1999; 15(2):3.
6. Nissen E, Widstrom AM, Lilja G, Matthiesen AS, Uvnas-Moberg K, Jacobsson G, Boreus LO. Effects of routinely given pethidine during labour on infants' developing breastfeeding behaviour. Effects of dose- delivery time interval and various concentrations of pethidine/norpethidine in cor d plasma. [Journal Article] Acta Paediatrica. 1997; 86(2):201-8.
7. McGuire W, Fowlie PW. Naloxone for narcotic exposed newborn infants: systematic review.Archives of Disease in Childhood Fetal & Neonatal Edition. 2003; 88(4):F308-11.
8. Barker D, Osmond C. Infant mortality, childhood nutrition and ischaemic heart disease in England and Wales. Lancet 1986;i:1077–
1081.
9. Osmond C, Barker DJP, Winter PD, et al. Early growth and death from cardiovascular disease in women. BMJ 1993; 307:1519–24.
10. Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie JW, Farewell V, Farine D, Spitzer K, Fielding L, Soloninka CA, Yeung M. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss New England Journal of Medicine. 1997; 337(3):148-53.
11. Murphy KE, Hannah M, Brocklehurst P. Are weekly courses of antenatal steroids beneficial or dangerous? JAMA.2002; 287(2):188.
12. Fisher JE, Smith RS, Lagrandeur R, Lorenz RP. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. [Journal Article] Obstetrics & Gynecology. 1997; 90(6):880- 3.
13. Wallace EM, Ekkel K, Cotter T, Tippett C, Catalano J. Haematological effects of betamethasone treatment in late pregnancy. [Journal Article] Australian & New Zealand Journal of Obstetrics & Gynaecology. 1998;38(4):396-8.
14. Canadian Perinatal Health report 2003.http://www.phac- aspc.gc.ca/publicat/cphr- rspc03/pdf/cphr-rspc03_e.pdf
15. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. New England Journal of Medicine.2005; 352(24):2477-86.
16. Dugoff L, Hobbins JC. Invasive procedures to evaluate the fetus. Clinical Obstetrics & Gynecology. 2002;45(4):1039-53.